M&A Advisor for Behavioral Health Practice Owners: 2026 Sell-Side Guide

By Christoph Totter, CT Acquisitions Managing Partner. Last reviewed: July 2026.

An M&A advisor for a behavioral health practice is a sell-side or buy-side investment banker or boutique corporate finance firm that specializes in outpatient mental health, substance use disorder (SUD), autism (ABA), and integrated behavioral care transactions in the roughly $1M to $50M lower middle market (LMM). This 2026 guide covers who the named specialist firms are, which private equity platforms and strategics are actively buying, how payer mix and 42 CFR Part 2 shape diligence, and how a practice owner should evaluate an advisor before signing an engagement letter.

Executive summary

Behavioral health has been one of the most consolidated healthcare subsectors of the past five years, with named PE platforms including Refresh Mental Health (acquired by Optum in 2022, per UnitedHealth Group press ) and LifeStance Health (public, per LifeStance S-1/A on SEC EDGAR ).

• Behavioral health has been one of the most consolidated healthcare subsectors of the past five years, with named PE platforms including Refresh Mental Health (acquired by Optum in 2022, per UnitedHealth Group press) and LifeStance Health (public, per LifeStance S-1/A on SEC EDGAR).
• PE and strategic acquirers active in the space include Centerbridge Partners (Mindpath Health, per Centerbridge), Webster Equity Partners (Discovery Behavioral Health, per Webster Equity), and Trinity Hunt Partners (Odyssey Behavioral Healthcare, per Trinity Hunt).
• Named boutique advisors that publish behavioral health thought leadership include Provident Healthcare Partners, Cain Brothers (a division of KeyBanc Capital Markets), and Ziegler.
• Regulatory diligence is heavier than average general medical M&A, driven by 42 CFR Part 2 for SUD records, MHPAEA for payer parity, and DEA rulemaking on controlled-substance telehealth prescribing.
• ABA (Applied Behavior Analysis) for autism is a separate regulatory and reimbursement track, driven by state Medicaid and commercial payer credentialing rather than Medicare, per CMS Medicaid.gov.
• Lower middle market practice-level multiples in behavioral health are not consistently disclosed and would range widely based on payer mix, provider retention, and platform vs tuck-in status.

Key findings

Behavioral health stayed one of the more active healthcare services subsectors, with 155 reported behavioral health transactions in 2024, per Mertz Taggart’s Q4 2024 Behavioral Health M&A Report. LifeStance Health, a public outpatient mental health platform (NASDAQ: LFST), disclosed in its S-1/A that it had grown by acquiring hundreds of clinician-owned practices between 2017 and 2021.

1. Behavioral health stayed one of the more active healthcare services subsectors, with 155 reported behavioral health transactions in 2024, per the Mertz Taggart Q4 2024 Behavioral Health M&A Report, with further context in Baker Tilly M&A commentary.
2. LifeStance Health, a public outpatient mental health platform (NASDAQ: LFST), disclosed in its S-1/A that it had grown by acquiring hundreds of clinician-owned practices between 2017 and 2021.
3. Optum’s April 2022 acquisition of Refresh Mental Health (previously Kelso & Company backed) is the largest disclosed behavioral health platform transaction of the last cycle, per UnitedHealth Group press.
4. Community Psychiatry rebranded to Mindpath Health under Centerbridge Partners ownership, per Centerbridge portfolio disclosures and Mindpath Health.
5. Discovery Behavioral Health is a Webster Equity Partners portfolio company, per Webster Equity Partners portfolio page.
6. Odyssey Behavioral Healthcare is a Trinity Hunt Partners portfolio company, per Trinity Hunt Partners portfolio page.
7. The Mental Health Parity and Addiction Equity Act (MHPAEA) 2024 final rule added new requirements for non-quantitative treatment limitation analyses, but on May 15, 2025 the Departments of Labor, HHS and Treasury said they would not enforce the rule’s new provisions while they reconsider it, per the U.S. Department of Labor EBSA.
8. 42 CFR Part 2, which governs the confidentiality of SUD patient records, was aligned more closely with HIPAA under a February 2024 SAMHSA/HHS final rule, per SAMHSA press.
9. DEA and HHS extended the COVID-era telehealth flexibilities for controlled-substance prescribing through December 31, 2026 (fourth temporary extension, Federal Register, December 31, 2025), per DEA Diversion Control, which affects psychiatry-forward practices with heavy stimulant or buprenorphine volume.
10. ABA autism therapy reimbursement is anchored in state Medicaid EPSDT and commercial payer contracts, not Medicare, per CMS Medicaid.gov.

Behavioral health M&A in 2026: what the deal data shows

Deal activity has leveled off at a high base. Capstone Partners’ Behavioral Healthcare Services M&A Update (July 2026) counts 44 deals announced or completed in 2026 through mid-year, one fewer than the same period of 2025. That follows a strong 2025, when Capstone reports sector volume rose 44.1% year over year after a 24.4% dip in 2024.

The buyer mix has shifted. Capstone reports that strategic buyers accounted for 68.2% of 2026 sector volume so far, with private equity add-ons less active than in past years and few new platforms formed. Two 2026 deals show where strategic money is going, per the same report: Talkspace (Nasdaq: TALK) was acquired by NYSE-listed UHS in March 2026 for $835 million, and Spring Health acquired Alma in May 2026, pairing a mental health platform with software that connects patients to therapists.

For a practice owner choosing a behavioral health M&A advisor, this matters in two ways. First, ask how many of the advisor’s recent deals closed with strategic buyers, not only private equity, because strategics are doing most of the buying right now. Second, Capstone flags Medicaid coverage changes as a live risk for the sector, so a Medicaid-heavy practice needs an advisor who can show buyers how its payer mix holds up under those changes.

What are the illustrative multiples by size band for behavioral health practices?

The table below shows illustrative frameworks for how behavioral health practices would typically be discussed in lower middle market M&A conversations. Practice-level multiples are not consistently disclosed, so the ranges below would need to be validated against the specific practice’s payer mix, provider concentration, and platform status. Blending revenue and EBITDA ranges would be a category error, and this report keeps them separate.

The table below shows illustrative frameworks for how behavioral health practices would typically be discussed in lower middle market M&A conversations. Practice-level multiples are not consistently disclosed, so the ranges below would need to be validated against the specific practice’s payer mix, provider concentration, and platform status. Blending revenue and EBITDA ranges would be a category error, and this report keeps them separate.

Size band (Adj. EBITDA)	Buyer profile	Illustrative EBITDA multiple range	Structure notes
Under $1M	Individual buyer, small platform tuck-in	Would typically fall in the low single digits	Often asset sale, seller note common
$1M to $3M	PE-backed platform tuck-in	Would generally clear mid single digits	Rollover equity often 10 to 20 percent
$3M to $10M	PE platform add-on, strategic	Would range into high single digits to low double digits	Earnouts tied to provider retention
$10M to $25M+	Platform deal, PE sponsor	Would clear low double digits or higher for scarce assets	Full sponsor process, QoE and clinical diligence

These ranges are illustrative and would need to be validated against comparable disclosed transactions and current sponsor bid sheets, which are not systematically public at the practice level. For a broader multiples context, see CT’s dermatology multiples guide and physical therapy multiples guide, both of which cover healthcare services size-band pricing more comprehensively.

What moves the multiple for a behavioral health practice

The following drivers explain most of the practice-to-practice variance a sell-side advisor would model. Each carries a source or a concrete example.

The following drivers explain most of the practice-to-practice variance a sell-side advisor would model. Each carries a source or a concrete example.

1. Payer mix. Commercial payer concentration would typically command a premium versus Medicaid-heavy books, though Medicaid contracts in some states have been repriced upward, per MACPAC behavioral health in Medicaid.
2. Provider retention. Psychiatrist, PMHNP, and licensed therapist retention post-close is the single most stress-tested clinical assumption in diligence, per Baker Tilly commentary.
3. Credentialing pipeline. The number of days from a new hire’s start to first billable session directly affects run-rate revenue.
4. Modality mix. Psychiatry, therapy, ABA, SUD, and eating disorders each have distinct reimbursement, staffing, and regulatory profiles, per SAMHSA data.
5. Telehealth exposure. DEA controlled-substance prescribing rules would affect stimulant and buprenorphine tele-volume, per DEA.
6. MHPAEA compliance posture. Comparative-analysis documentation drives plan-level parity diligence, with the 2024 final rule’s new provisions unenforced since May 2025, per DOL EBSA.
7. 42 CFR Part 2 hygiene. SUD-treating practices with clean Part 2 consent records and audit trails would diligence faster, per SAMHSA.
8. State licensure and CPOM. Corporate practice of medicine varies by state, per AMA CPOM issue brief.
9. ABA-specific regulation. ABA practices face state Medicaid credentialing and BCBA supervision ratios, per BACB.
10. Same-store growth trajectory. Sponsors would generally underwrite the last two years of same-clinic session volume, not just aggregate revenue.
11. Physical footprint and lease optionality. Practices with clean leases and expansion rights would carry less real estate risk.
12. Concentration of a single referral source or payer contract. Any single-source contract above roughly 20 percent of revenue would be flagged in a quality of earnings review.
13. Denial rate and days in AR. Denials above single-digit percentages are typically renegotiation levers in a QoE.
14. Adjusted EBITDA hygiene. Owner comp, real estate rent normalization, and one-time COVID revenue adjustments are typical add-backs, per CT’s insurance-agency guide’s QoE section.
15. Scarcity of platforms. Sponsors seeking a new platform in a subsector (for example, eating disorders or perinatal mental health) would pay a scarcity premium.
16. ARPA-era wage inflation reversion. Clinician wage inflation between 2021 and 2024 has repriced staffing baselines, per BLS OES 21-1014 (mental health counselors).
17. Clinical outcomes documentation. Practices with PHQ-9, GAD-7, and CGI outcome dashboards would frame value-based care readiness better.

Who are the active buyers in behavioral health M&A?

Private equity platforms

The named PE-backed platforms below are the largest disclosed behavioral health consolidators of the last cycle. Each entry is sourced to a public URL, not a general recollection.

• LifeStance Health (NASDAQ: LFST). Publicly traded outpatient mental health platform, previously TPG-backed before its 2021 IPO, per S-1/A on SEC EDGAR.
• Refresh Mental Health, acquired by Optum in 2022. Optum, a subsidiary of UnitedHealth Group, acquired the Kelso-backed behavioral health platform, per UnitedHealth Group press.
• Mindpath Health, Centerbridge Partners. Rebranded from Community Psychiatry, backed by Centerbridge Partners.
• Discovery Behavioral Health, Webster Equity Partners. Confirmed as a Webster portfolio company, per Webster Equity Partners.
• Odyssey Behavioral Healthcare, Trinity Hunt Partners. Confirmed as a Trinity Hunt portfolio company, per Trinity Hunt Partners.

Strategic acquirers

Strategic acquirers include health plans and integrated health systems. Optum’s Refresh Mental Health acquisition, cited above per UnitedHealth Group, is the reference transaction for payer-strategic acquisition of an outpatient behavioral platform. Strategic buyers typically underwrite deals differently than sponsors, focusing on medical loss ratio impact, provider network fill, and cross-sell into a larger membership base rather than short-hold IRR.

Which boutique M&A advisors specialize in behavioral health?

The named boutique corporate finance firms below publish behavioral health M&A commentary and have disclosed behavioral health transactions. Each is described neutrally, with an official URL. This section is intended to give a sell-side prospect a starting shortlist rather than a ranking.

The named boutique corporate finance firms below publish behavioral health M&A commentary and have disclosed behavioral health transactions. Each is described neutrally, with an official URL. This section is intended to give a sell-side prospect a starting shortlist rather than a ranking.

• Provident Healthcare Partners. A healthcare-only boutique investment bank in Boston that maintains a dedicated behavioral health practice and publishes recurring sector reports on outpatient mental health, SUD, and autism services.
• Cain Brothers. A division of KeyBanc Capital Markets that covers healthcare services including behavioral health, generally advising on larger platform transactions than pure LMM.
• Ziegler. A specialty investment bank that covers behavioral health and other senior living and post-acute healthcare verticals.

Other specialty M&A firms active in the behavioral health space would be evaluated on the same criteria as the named firms above: disclosed transaction history, sector reports, buyer relationships, and fit with the seller’s size band.

More behavioral health M&A firms owners shortlist

Beyond the three boutiques above, these firms show up most often when owners search for a behavioral health M&A advisor or a mental health M&A firm. Each description is based on the firm’s own published material, not a ranking.

• Houlihan Lokey. A large investment bank with a dedicated behavioral healthcare team inside its healthcare group, generally focused on larger platform and middle market deals.
• Mertz Taggart. A healthcare M&A advisory firm focused on behavioral health, home health, and home care, which publishes a quarterly Behavioral Health M&A Report.
• VERTESS. A Fort Worth, Texas based healthcare M&A advisory firm that represents sellers of healthcare services companies, including behavioral health providers.
• Agenda Health. A healthcare advisory firm with a behavioral health M&A practice and a network of behavioral health businesses for sale.
• Capstone Partners. A middle market investment bank that publishes the Behavioral Healthcare Services M&A Update cited above.

Use the checklist further down this page to compare any of them. Ask each one for its behavioral health deals closed in the last three years, at your size, and with the buyer types you want. A firm built for $50 million platform sales may not give a $2 million EBITDA practice senior attention, and a firm that mostly lists small practices may not reach the platforms and strategics that pay the most.

Where CT Acquisitions fits

CT Acquisitions is another lower middle market option for behavioral health practice owners in the roughly $1M to $50M enterprise-value range. CT’s model is owner-aligned fees and a vetted institutional buyer network, and the firm positions itself as an LMM specialist rather than a sector-only shop.

CT Acquisitions is another lower middle market option for behavioral health practice owners in the roughly $1M to $50M enterprise-value range. CT’s model is owner-aligned fees and a vetted institutional buyer network, and the firm positions itself as an LMM specialist rather than a sector-only shop. For a full description of the CT engagement model, see the CT M&A advisory pillar, the 2026 fee guide, and how an M&A advisor differs from a business broker. Behavioral health owners deciding among CT, Provident, Cain Brothers, Ziegler, or another firm would typically weigh sector-specific transaction history and buyer relationships against firm size, senior banker attention, and fee alignment.

How the sell-side process works for a behavioral health practice

A typical sell-side process for a behavioral health practice would run roughly six to nine months from engagement to close, longer if payer credentialing transfers or Part 2 record migrations complicate the transition. The month-by-month view below is a working template, not a guarantee.

A typical sell-side process for a behavioral health practice would run roughly six to nine months from engagement to close, longer if payer credentialing transfers or Part 2 record migrations complicate the transition. The month-by-month view below is a working template, not a guarantee. For a broader treatment of the sell-side timeline, see CT’s investment banking process guide and sell-side advisory maximize your exit value.

Month 1 to 2: preparation

The advisor would build a data room, normalize adjusted EBITDA with a third-party quality of earnings firm, and map payer mix, credentialing status, and Part 2 consent hygiene. See CT’s QoE deep dive.

Month 2 to 3: marketing materials

A confidential information memorandum and teaser would be drafted, with a buyer list segmented into PE platforms, strategic acquirers, and health-plan strategics. Named platforms per LifeStance’s S-1, UnitedHealth’s Optum press, and Webster’s portfolio page would typically feature on that list.

Month 3 to 5: buyer outreach and LOI

Buyers would receive the teaser under an NDA, then the CIM. Management meetings would follow, and the process would drive to indications of interest and then a letter of intent. See CT’s LOI template.

Month 5 to 7: confirmatory diligence

Legal, financial, clinical, regulatory, and IT diligence run in parallel. Clinical diligence includes provider credentialing files, malpractice history, and outcomes documentation. Regulatory diligence includes MHPAEA posture, 42 CFR Part 2, and any DEA registration issues per the sources cited above. See CT’s due diligence checklist.

Month 7 to 9: signing and closing

Definitive purchase agreements, rollover equity documentation, escrow, and provider employment or independent contractor transition agreements would be negotiated and executed.

What are the regulatory and structural mechanics for behavioral health M&A in 2026?

Mental Health Parity and Addiction Equity Act (MHPAEA)

MHPAEA requires group health plans to cover mental health and SUD benefits at parity with medical and surgical benefits. Plans must still document comparative analyses of non-quantitative treatment limitations, while enforcement of the 2024 final rule’s new provisions has been paused since May 15, 2025, per DOL EBSA. Practices with strong data on plan-level session authorizations would show better in diligence.

42 CFR Part 2 (SUD records)

Any practice touching SUD records is governed by 42 CFR Part 2. The February 2024 HHS final rule aligned Part 2 more closely with HIPAA, per SAMHSA press, but consent architecture is still stricter than general HIPAA.

DEA controlled-substance telehealth prescribing

The DEA extended COVID-era telehealth flexibilities through the end of 2025, per DEA Diversion Control. Any practice relying heavily on tele-prescribing for stimulants or buprenorphine would need to model the possibility of a rule that requires an initial in-person visit for controlled substances.

State corporate practice of medicine (CPOM)

States including California, Texas, and New York restrict non-physician ownership of medical practices, per the AMA CPOM issue brief. Behavioral health platforms in those states typically use management services organization (MSO) structures.

ABA and state Medicaid credentialing

ABA practices for autism serve mostly pediatric Medicaid populations, per CMS Medicaid.gov. BCBA supervision ratios and Registered Behavior Technician credentialing, per BACB, drive both clinical quality and reimbursement.

How to choose an M&A advisor for a behavioral health practice

Compare firms before signing an engagement letter on three points: sector transaction history, buyer relationships, and payer mix expertise.

A checklist to compare firms before signing an engagement letter:

1. Sector transaction history. Ask for a list of disclosed behavioral health transactions the specific team has closed in the last 36 months, not the firm’s aggregate healthcare list.
2. Buyer relationships. Ask which named PE platforms and strategics the advisor has directly transacted with. Cross-check against the platforms cited above.
3. Payer mix expertise. Confirm the advisor understands MHPAEA, Part 2, and state Medicaid ABA reimbursement mechanics.
4. QoE partner alignment. Ask which QoE firms the advisor typically works with and whether the QoE team has behavioral health depth.
5. Fee structure. Compare retainer, success fee ladder, and minimum fee. See CT’s retainer guide and fee structure guide.
6. Senior banker attention. Ask which senior banker will run the process day to day, not who pitches at the beauty parade.
7. References from prior sellers. Ask for two seller references at your size band, ideally in behavioral health.
8. Process fit for size band. A bulge bracket process is a mismatch for a $3M EBITDA practice; a broker-style process is a mismatch for a $15M EBITDA platform. See M&A advisor vs business broker.
9. Rollover equity and management economics. Confirm the advisor has structured deals with rollover equity, MIP shares, and earnouts.
10. Buyer-type coverage. Ask whether the advisor has transacted with search funds, family offices, and strategics, or only PE. See search fund vs PE, family office vs PE, and strategic vs financial buyer.
11. Post-LOI leverage. Confirm the advisor stays involved through confirmatory diligence and does not disengage after LOI.
12. Cultural fit. The advisor will spend six to nine months inside the practice’s books. Cultural fit is a real underwriting question.

What EBITDA multiples apply by deal size in 2026?

EBITDA multiples for lower middle market businesses vary by size, buyer type, and vertical. The table below shows typical bands for privately-held sellers in 2026 based on GF Data and Axial 2025 benchmarks.

EBITDA size band	Typical multiple	Dominant buyer type
$500K to $1M	3.0x to 4.5x	Individual buyers, ETA, small local PE
$1M to $3M	4.0x to 6.0x	Search funds, small PE, family offices
$3M to $10M	5.5x to 8.0x	Lower middle market PE, strategic tuck-ins
$10M to $25M	7.0x to 10.5x	Middle market PE platforms, strategic acquirers

Frequently asked questions

What does an M&A advisor for a behavioral health practice do?

An M&A advisor prepares the practice for sale, builds and runs a competitive buyer process, normalizes financials for a quality of earnings review, negotiates the letter of intent and definitive agreement, and manages payer, credentialing, and regulatory diligence through close. Named specialists include Provident Healthcare Partners, Cain Brothers, and Ziegler, per their published behavioral health coverage.

How much does an M&A advisor cost for a behavioral health practice?

Fees would typically include a monthly retainer, a success fee based on transaction value using a Lehman-style or modified Lehman ladder, and expense reimbursements. LMM engagement economics are covered in more detail in the 2026 M&A advisor fees guide and the M&A advisor cost overview.

Which private equity firms are buying behavioral health practices in 2026?

Active named platforms include LifeStance Health (public), Mindpath Health (Centerbridge Partners), Discovery Behavioral Health (Webster Equity Partners), and Odyssey Behavioral Healthcare (Trinity Hunt Partners). Optum, per its April 2022 acquisition of Refresh Mental Health, is the reference payer-strategic buyer.

What multiples do behavioral health practices sell for?

Practice-level multiples are not consistently disclosed. Illustrative frameworks would place sub-$1M EBITDA practices in the low single digits and platform-scale practices in the low double digits or higher, but any range would need to be validated against payer mix, provider retention, and platform status. Comparable guidance for adjacent healthcare verticals is in CT’s dermatology multiples guide.

How long does it take to sell a behavioral health practice?

A typical sell-side process would take six to nine months from engagement letter to close, plus any post-close credentialing transfer and integration. Payer credentialing transfers and Part 2 record migrations frequently extend the closing timeline.

Do I need a specialist advisor, or will a generalist LMM advisor work?

Behavioral health has enough payer, regulatory (MHPAEA, 42 CFR Part 2, DEA telehealth, state CPOM), and clinical diligence complexity that a generalist advisor without healthcare depth would typically be a mismatch. A generalist LMM firm with a strong healthcare team, paired with a QoE partner with behavioral health depth, would be acceptable. A generalist without any healthcare bench would not.

Should I sell to Optum, LifeStance, or a PE-backed platform?

The right buyer depends on rollover equity appetite, cultural fit, cash consideration priority, and management continuity. A competitive process run by a specialist advisor would put all three buyer types in front of the seller, so the seller does not have to pre-select. See CT’s strategic vs financial buyer guide.

What is 42 CFR Part 2 and why does it matter in behavioral health M&A?

42 CFR Part 2 governs the confidentiality of SUD patient records and requires stricter consent architecture than general HIPAA, per the eCFR. Practices with clean Part 2 consent records diligence faster and would face fewer post-close indemnity holdbacks.

Which M&A firms specialize in behavioral health?

Firms that publish behavioral health deal research or run dedicated teams include Provident Healthcare Partners, Cain Brothers, Ziegler, Houlihan Lokey, Mertz Taggart, VERTESS, Agenda Health, and Capstone Partners. They differ mainly in deal size and buyer reach. Ask each for behavioral health deals it closed at your size in the last three years, and for two seller references.

Is behavioral health M&A slowing down in 2026?

It has leveled off rather than dropped. Capstone Partners counted 44 behavioral healthcare services deals in 2026 through mid-year, one fewer than the same period of 2025, after a strong 2025. Strategic buyers have done most of the 2026 buying, while private equity add-on activity has been lighter than in prior years.

Methodology and data sources

This guide was compiled by CT Acquisitions using publicly available SEC filings, PE and portfolio disclosures, federal regulatory publications, and named sector-specialist commentary.

This guide was compiled by CT Acquisitions using publicly available SEC filings, PE and portfolio disclosures, federal regulatory publications, and named sector-specialist commentary. Named sources include the SEC EDGAR system for LifeStance Health’s S-1/A, UnitedHealth Group press releases for the Refresh Mental Health transaction, portfolio pages of Centerbridge Partners, Webster Equity Partners, and Trinity Hunt Partners, published sector commentary from Provident Healthcare Partners, Cain Brothers, Ziegler, and Baker Tilly, U.S. Department of Labor EBSA publications on MHPAEA, SAMHSA publications on 42 CFR Part 2, DEA Diversion Control publications on controlled-substance telehealth prescribing, CMS Medicaid.gov publications on ABA and behavioral health benefits, BLS OES wage tables, the AMA corporate practice of medicine issue brief, and the Behavior Analyst Certification Board.

Practice-level valuation ranges are illustrative and would need to be validated against the specific practice’s payer mix, provider retention, credentialing pipeline, modality mix, and quality of earnings analysis. Multiples are not consistently disclosed at the practice level in behavioral health, and any range in this guide is intended as a framework for discussion rather than a comparable-transaction citation.

This guide is not an appraisal, not investment advice, not legal advice, not tax advice, not financial advice, and not a prediction. Nothing in this guide constitutes a solicitation or an offer. Any transaction would depend on the specific facts and circumstances of the practice, its payer contracts, its regulatory posture, and the market environment at the time of engagement. Business owners considering a transaction should engage qualified legal, tax, and financial advisors of their own.